Clinical experience with a novel endotoxin adsorbtion device in patients undergoing cardiac surgery

Abstract

Endotoxaemia is thought to occur in cardiac surgery using extracorporeal circulation (ECC) and a positive correlation has been proposed between the magnitude of endotoxaemia and risk for postoperative complications. We studied the effects of a new endotoxin adsorber device (Alteco® LPS adsorber) in patients undergoing cardiac surgery with ECC, with special reference to safety and ease of use. Fifteen patients undergoing coronary artery bypass and/or valvular surgery were studied. In 9 patients, the LPS Adsorber was included in the bypass circuit between the arterial filter and the venous reservoir. Flow through the adsorber was started when the aorta was clamped and stopped at the end of perfusion. Flow rate was kept at 150 ml/min. Six patients served as controls with no adsorber in the circuit. Samples were taken for analysis of endotoxin, TNFα, IL-1ß and IL-6 as well as complement factors C3, C4 and C1q. Whole blood coagulation status was evaluated using thromboelastograpy (TEG) and platelet count. No adverse events were encountered when the adsorber was used in the circuit. Blood flow through the device was easily monitored and kept at the desired level. Platelet count decreased in both groups during surgery. TEG data revealed a decrease in whole blood clot strength in the control group while it was preserved in the adsorber group. Endotoxin was detected in only 2 patients and IL-1ß in 4 patients. IL-6 decreased in both groups whereas no change in TNF concentrations was found. C3 fell in both groups, but no changes wer found in C4 and C1q. The Alteco® LPS adsorber can be used safely and is easy to handle in the bypass circuit. No complications related to the use of the adsorber were noted. The intended effects of the adsorber, i.e. removal of endotoxin from the blood stream could not be evaluated in this study, presumably due to the small number of patients and the relatively short perfusion times.

Keywords

adsorbtion cardiopulmonary bypass endotoxin inflammatory mediators

Get full access to this article

View all access options for this article.

References

1 Chenoweth DE Cooper SW Hugli T Stewart R Blackstone E Kirklin J . Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylotaxins. N Engl J Med 1981; 304(9): 497–503.

2 Kirklin JK Westaby S Blackstone EH Kirklin JW Chenoweth DE Pacifico AD . Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983; 86(6): 845–857.

3 Butler J Rocker GM Westaby S . Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 552–559.

4 Baldwin WM Pruitt SK Brauer RB Daha MR Sanfilippo F . Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation 1995; 59(6): 797–808.

5 Bhole D Stahl GL . Therapeutic potential of targeting the complement cascade in critical care medicine. Crit Care Med 2003; 31(1): S97–S104.

6 Dong J Pratt JR Smith RA Dodd I Sacks SH . Strategies for targeting complement inhibitors in ischaemia/reperfusion injury. Mol Immunol 1999; 36: 957–963.

7 Danner RL Elin RJ Hosseini JM Wesley RA Reilly JM Parillo JE . Endotoxin in human septic shock. Chest 1991; 99: 169–175.

8 Venkatamaran R Subramanian S Kellum JA . Clinical review: extracorporeal blood purification in severe sepsis. Critical Care 2003; 7: 139–145.

9 Shoji H . Extracorporeal endotoxin removal for the treatment of sepsis. Endotoxin adsorbtion cartridge (Toramycin). Ther Apher&Dial 2003; 7: 108–114.

10.

10 Vincent J-L Laterre P-F Cohen J . A pilot-controlled study of a polymyxin B immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra abdominal infection. Shock 2005; 23: 400–405.

11.

11 Levy JH Tanaka KA . Inflammatory response to cardiopulmonary bypass. Ann Thor Surg 2003; 75: S175.

12.

12 Ohki S Oshima K . Takeyoshi, I, et al. Endotoxin removal with a polymyxin B-immobilized hemoperfusion cartridge improves cardiopulmonary function after cardiopulmonary bypass. J Surg Res 2008; 145: 74–79.

13.

13 Kulabukhov VV . Use of an endotoxin adsorber in the treatment of severe abdominal sepsis. Acta Anaesthesiol.Scand 2008; 57: 1024–1025.

14.

14 Kojika M Sato N Yaegashi Y . Endotoxin adsorbtion therapy for septic shock using polymyxin B-immobilized fibers (PMX). Evaluation by high-sensitivity endotoxin assay and measuremet of the cytokine production capacity. Ther Apher Dial 2006; 10: 12–18.